Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 2/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 11/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3160158 | 0.87 | HRH3 (0.47) | CHRNA7HRH3CYP2D6CNR2 | |
| SCHEMBL3160554 | 0.86 | KMT2A (0.48) | HRH3CYP2D6CNR2ALDH1A1GAA | |
| SCHEMBL3177575 | 0.86 | CHRNA7 (0.51) | CHRNA7HRH3CYP2D6SLC6A4 | |
| SCHEMBL3539403 | 0.86 | CHRNA7 (0.56) | CHRNA7HRH3CYP2D6 | |
| SCHEMBL3538951 | 0.85 | CHRNA7 (0.50) | CHRNA7HRH3CYP2D6ALDH1A1SLC6A4 | |
| SCHEMBL3541236 | 0.85 | HRH3 (0.62) | CHRNA7HRH3CYP2D6SLC6A4 | |
| SCHEMBL3169749 | 0.85 | HRH3 (0.50) | CHRNA7HRH3CYP2D6CNR2 | |
| SCHEMBL3160495 | 0.85 | CHRNA7 (0.54) | CHRNA7HRH3CYP2D6ALDH1A1 | |
| SCHEMBL3160162 | 0.83 | TSHR (0.50) | CHRNA7HRH3CYP2D6CNR2ALDH1A1 | |
| SCHEMBL3160773 | 0.83 | CHRNA7 (0.48) | CHRNA7HRH3CYP2D6ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7648979-B2 | 5-amido-(1H-indol-2-yl)-piperazin-1-yl-methanone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-01-19 | — | — | US | claimed |
| EP-2118059-A1 | 5 -AMIDO- (IH- INDOL- 2 -YL) PIPERAZIN-1-YL-METHANONE DERIVATIVES AS HISTAMINE H3 RECEPTOR LIGANDS | F. Hoffmann-Roche AG (CH) | 2009-11-18 | — | — | EP | claimed |
| WO-2008095823-A1 | 5 -AMIDO- (IH- INDOL- 2 -YL) PIPERAZIN-1-YL-METHANONE DERIVATIVES AS HISTAMINE H3 RECEPTOR LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-08-14 | — | — | WO | claimed |
| US-20080188487-A1 | 5-AMIDO-(1H-INDOL-2-YL)-PIPERAZIN-1-YL-METHANONE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2008-08-07 | — | — | US | claimed |
| US-7648979-B2 | 5-amido-(1H-indol-2-yl)-piperazin-1-yl-methanone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-01-19 | — | — | US | disclosed |
| EP-2118059-A1 | 5 -AMIDO- (IH- INDOL- 2 -YL) PIPERAZIN-1-YL-METHANONE DERIVATIVES AS HISTAMINE H3 RECEPTOR LIGANDS | F. Hoffmann-Roche AG (CH) | 2009-11-18 | — | — | EP | disclosed |
| WO-2008095823-A1 | 5 -AMIDO- (IH- INDOL- 2 -YL) PIPERAZIN-1-YL-METHANONE DERIVATIVES AS HISTAMINE H3 RECEPTOR LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-08-14 | — | — | WO | disclosed |
| US-20080188487-A1 | 5-AMIDO-(1H-INDOL-2-YL)-PIPERAZIN-1-YL-METHANONE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2008-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188487-A1 | 5-AMIDO-(1H-INDOL-2-YL)-PIPERAZIN-1-YL-METHANONE DERIVATIVES | HRH4, HRH3, HRH2 | CHRNA7 129/4885HRH3 2/4885CYP2D6 462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.